## Key Points 1. Most liver transplant allograft recipients require long-term immunosuppression, and the most popular therapeutic regimen includes induction therapy, calcineurin inhibitors, corticosteroids, and mycophenolate. 2. Tailoring currently available drugs to the individual may allow bette
The new immunosuppression
β Scribed by Herman Waldmann
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 201 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1367-5931
No coin nor oath required. For personal study only.
β¦ Synopsis
New knowledge on how lymphocytes become tolerant to antigens is now enabling novel tolerance-harnessing strategies to enter the clinical arena. In the field of transplantation, monoclonal antibodies used either to deplete lymphocytes or to block T-cell function can induce tolerance in mice and nonhuman primates. Understanding the mechanisms underlying tolerance should enable application to the clinic. Harnessing of tolerance mechanisms may enable more judicious use of conventional immunosuppressive agents even to the point of maintenance monotherapy, so limiting drug side effects and ensuring compliance.
π SIMILAR VOLUMES
## Abstract Calcineurin (CN), the Ca^2+^/calmodulin (CaM)βdependant protein phosphatase, is the target for immunosuppressive drugs cyclosporine A (CsA) and FK506. These immunosuppressants can inhibit CN activity after binding with respective immunophilins. Based on the model of screening by using _